First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer

NCT05586061 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

55

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Gastric Cancer

Interventions

DRUG: Disitamab vedotin
DRUG: Tislelizumab
DRUG: S1

Sponsor

Qilu Hospital of Shandong University